Introduction:

Sickle cell disease (SCD) is highly prevalent in Sub-Saharan Africa, contributing to 16% of mortality in Nigerian and Ghanaian children under 6 years of age. School-aged children with SCD experience recurrent illness, hospitalization, and disability due to complications. Oxidative stress contributes significantly to SCD pathophysiology. This study investigated Jobelyn®, a sorghum bicolor-based herbal supplement, for its effect on oxidative stress markers in SCD children. Jobelyn is available over the counter and is use by people living with SCD in Nigeria.

Methods:

This non-randomized, quasi-experimental study included 87 Jobelyn-naïve children with SCD (aged 5-17 years). Ethics approval was granted by the Lagos State University Teaching Hospital health research ethics committee. Parents and participants gave written consent and assent. Demographic data, full blood counts, and oxidative stress markers (Glutathione, superoxide dismutase, catalase, and malondialdehyde) were measured at baseline, 6 weeks, and 12 weeks after commencing Jobelyn supplementation. Children receiving hydroxyurea were not excluded.

Results:

Significant increases in Glutathione levels (p<0.0001) and decreases in superoxide dismutase, catalase, and malondialdehyde levels (p<0.0001) were observed at 6 and 12 weeks. Hemoglobin concentrations rose significantly (p<0.001) at 6 weeks, while white cell counts fell below steady state values (p<0.001). Both hydroxyurea-naïve and the near equal number of hydroxyurea-treated children all responded with statistically significant changes in oxidative stress markers.

Conclusion:

Jobelyn significantly reduced oxidative stress and improved hematological indices in school-aged Nigerian children with SCD. Further longitudinal studies and Jobelyn trials in children with SCD are recommended to determine its benefits and safety profile.

Disclosures

No relevant conflicts of interest to declare.

This content is only available as a PDF.
2024
Sign in via your Institution